Aduro Biotech Inc (ADRO)

10.95
NASDAQ : Health Care
Prev Close 10.95
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.75 / 16.43
Avg Volume 462.10K
Exchange NASDAQ
Shares Outstanding 69.91M
Market Cap 783.03M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aduro Biotech Announces FDA Clearance Of Investigational New Drug Application To Evaluate The Combination Of ADU-S100 With PDR001 For The Treatment Of Solid Tumors And Lymphomas

Early Phase 1 Dose Escalation Signals Support Advancement into Phase 1b in Second Half of 2017

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.

Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro's CRS-207 With Merck's KEYTRUDA® (Pembrolizumab) For The Treatment Of Mesothelioma

Second Phase 2 Clinical Collaboration between the Two Companies to Evaluate CRS-207/Pembrolizumab Combination

Aduro Biotech Reports First Quarter 2017 Financial Results

Ten Product Candidates Advancing with $356 Million in Total Cash

Oversold Conditions For Aduro Biotech (ADRO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of May 19th Options Trading For Aduro Biotech (ADRO)

Investors in Aduro Biotech Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADRO options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Commit To Buy Aduro Biotech At $7.50, Earn 17.6% Annualized Using Options

Investors considering a purchase of Aduro Biotech Inc shares, but tentative about paying the going market price of $10.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $7.50 strike, which has a bid at the time of this writing of 75 cents.

Aduro Biotech To Host Research And Development Day In New York

Company Also Invited to Ring the Opening Bell at the NASDAQ Stock Market

3 Stocks Setting Up for Major Breakouts

3 Stocks Setting Up for Major Breakouts

Here's how to rake in the gains off some potential major breakouts.

Commit To Purchase Aduro Biotech At $7.50, Earn 20.8% Annualized Using Options

Commit To Purchase Aduro Biotech At $7.50, Earn 20.8% Annualized Using Options

Investors considering a purchase of Aduro Biotech Inc shares, but cautious about paying the going market price of $10.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July 2017 put at the $7.50 strike, which has a bid at the time of this writing of 90 cents.

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

There's little to substantiate the president-elect's claim that he will bring drug prices down, but biotech investors are trading anyway.

Aduro Biotech Presents Preclinical Data Supporting Clinical Development Of Its Anti-APRIL Antibody, BION-1301, For The Treatment Of Multiple Myeloma

Aduro Biotech Presents Preclinical Data Supporting Clinical Development Of Its Anti-APRIL Antibody, BION-1301, For The Treatment Of Multiple Myeloma

Poster #2112 to be Presented at the 58th American Society of Hematology Annual Meeting and Exposition

Partial Clinical Hold Lifted And Enrollment Resumes For Aduro Biotech LADD Clinical Trials

Partial Clinical Hold Lifted And Enrollment Resumes For Aduro Biotech LADD Clinical Trials

Company's Ongoing Clinical Trials with LADD-based Therapies Include Mesothelioma and Ovarian Cancers as well as Personalized LADD (pLADD)